PROGRESS
The Use of Proa-active Monitoring by Measuring Vital Signs Using a Fitbit for a 3-month Period Before, During, and After Chemotherapy in Patients With Cancer
Sponsor study identifier
observational
175
1 country
1
Study Start
July 1, 2025
Actual (reported)Primary Completion
November 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The goal of this single center prospective observational study is to determine the effect of chemotherapy on (the change in) vital parameters. The main question it aims to answer are: Can changes in vital parameters be measured by using a Fitbit in patients with cancer while undergoing chemotherapy. Participants will be asked to wear a Fitbit for the first two cycles of chemotherapy to evaluate the changes in vital parameters.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 14, 2024
Actual (reported)November 8, 2024
Actual (reported)July 1, 2025
Actual (reported)November 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Variance and normalization of resting heart rate
Variance and normalization of resting heart rate in bpm over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of maximum heart rate
Variance and normalization of vital parameters maximum heart rate in bpm over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of minimum heart rate
Variance and normalization of minimum heart rate in bpm over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of heart rate variability
Variance and normalization of vital parameters heart rate variability over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of respiratory rate
Variance and normalization of respiratory rate in absolute numbers over time during chemotherapy
Through study completion, an average of 6 months
Contact with healthcare provider
Through study completion, an average of 6 months
emergency department visits
Through study completion, an average of 6 months
Toxicity
Through study completion, an average of 6 months
Dose Modification of chemotherapy
Through study completion, an average of 6 months
Age group
Through study completion, an average of 6 months
Sex
Through study completion, an average of 6 months
Cancer Type
Through study completion, an average of 6 months
All patients with stomach and esophageal malignancies referred for chemotherapy of the outpatient clinic at the department of Medical Oncology at the Erasmus University Medical Center.
Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
All patients with stomach and esophageal malignancies referred for chemotherapy of the outpatient clinic at the department of Medical Oncology at the Erasmus University Medical Center.
Erasmus University Medical Center
Rotterdam, South Holland, 3015GD, Netherlands
First Submitted
October 14, 2024
First Posted
November 8, 2024
Study Start
July 1, 2025
Actual (reported)Primary Completion
November 1, 2025
Estimated (date passed)Palliative Care Yields Cancer Wellbeing Support
Variance and normalisation of blood pressure
Variance and normalization of blood pressure in mmHG over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of step count
Variance and normalization of step count in absolute numbers over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of blood oxygen saturation
Variance and normalization of blood oxygen saturation in percentage over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of sleep time
Variance and normalization of sleep time in hours over time during chemotherapy
Through study completion, an average of 6 months
Variance and normalisation of sleep quality
Variance and normalization of sleep quality on a scale from 1 to 10 over time during chemotherapy
Through study completion, an average of 6 months
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 13, 2025
Record last verified: 2025-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: